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Clinical case
Gemcitabine-induced systemic capillary leak syndrome
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Summary
Systemic capillary leak syndrome (SCLS) is a rare disorder
with a high mortality rate, characterized by rapidly developing
edema, weight gain and hypotension, hemoconcentration and
hypoproteinemia This syndrome is caused by sudden, rever-
sible capillary hyperpermeabihty with a rapid extravasation of
plasma from the intravascular to the interstitial space Even
though SCLS has been suggested to be the pathogenic mecha-
nism for the pulmonary toxicity of gemcitabine (GCB), a new
deoxycytidine analogue with structural similarities to cytosine
arabinoside, a direct correlation between GCB and SCLS has
never been reported We describe a case of repeated SCLS after
GCB administration in a 51-year-old male with locally-ad-
vanced non-small-cell lung cancer treated with a combination
of cisplatin and GCB The detection of GCB-induced SCLS
supports the hypothesis that SCLS could be the pathogenic
way of GCB pulmonary toxicity This finding can help to better
understand and treat the potentially deadly GCB-related acute
respiratory distress syndrome that is being recognized
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Introduction
Systemic capillary leak syndrome (SCLS) is a rare dis-
order caused by a sudden, reversible capillary hyper-
permeability with a rapid extravasation of plasma from
the intravascular to the interstitial space. The most usual
mechanisms inducing capillary leak relate to an increased
size of the transcapillary transport passages by endothe-
lial cell contraction. This results in a rapidly developing
edema, hypotension and weight gain, hemoconcentra-
tion and possible renal shutdown.
This syndrome, described after snake bites [1] and in
patients with sepsis [2, 3], is a well-known pathogenic
way of toxicity for many drugs, including recombinant
interleukin-2 [4] and Taxotere [5].
SCLS has also been suggested to be the pathogenic
mechanism of the pulmonary toxicity of gemcitabine [6]
(GCB), a new deoxycytidine with structural similarities
to cytosine arabinoside, with confirmed antitumor activity
in patients with non-small-cell lung cancer (NSCLC).
Nevertheless, to our knowledge, a direct correlation
between GCB administration and SCLS has never been
reported.
We describe a case of repeated SCLS induced by
GCB administration in an adult patient with locally-
advanced NSCLC.
Case report
A 51-year-old male with stage Ilia non-small-cell lung
cancer (NSCLC) was treated in our Institute with induc-
tion chemotherapy containing cisplatin (CDDP) plus
gemcitabine (GCB)
Clinical and anamnestic findings revealed no signs
of cough, swelling or dyspnea. Physical examination,
cardiologic- and pulmonary-function evaluation were
unremarkable.
The patient received CDDP 80 mg/m2, administered
as a one-hour infusion on day 1, and GCB 1250 mg/m2
administered as a 30-min infusion on day 1 and 8,
repeated every three weeks.
Treatment given on day 1 was preceded by desa-
metasone 8 mg I v. and granisetron 3 mg i.v. for the
prophylaxis of nausea and vomiting; dexamethasone
4 mg i.v. was also given 12 hours after CDDP admin-
istration. The same anti-emetic treatment was repeated
intravenously on day 2 and orally on days 3 and 4.
Hydration with 3000 cc/day of saline and electrolytes
supplementation was administered on a 48-hour infu-
sion, starting 12 hours before treatment. The first treat-
ment cycle was uneventful.
Two days after GCB administration on day 8 of the
second cycle, the patient was admitted to our Institute
with worsening dyspnea, diffuse swelling, weight gain
and hypotension.
No alterations of blood count, serum electrolytes or
renal function were registered. Despite albumin admin-
istration, the values of total protein hardly decreased
during hospitalization (down to 6 3 g/1); proteinuria was
excluded by urine examination.
Ventricular dysfunction, superior vena cava compres-
sion or thrombosis and lung infiltrates were excluded
by echocardiography and thorax spiral CT scan. CT
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scan also documented an evident disease response.
Intravenous administration of Furosemide and high-
dose dexamethasone was promptly given, with complete
symptom recovery within two days.
The third treatment cycle was given on time, with a
25% dose reduction of both CDDP and GCB.
The patient was readmitted to our institute 48 hours
after day-8 GCB administration. He suffered again from
severe dyspnea, diffuse swelling and hypotension. Blood
examination showed pancytopenia (PLT. 34 x 109/l,
WBC 2 0 x 1O9/I, Hb 7.8 g/dl), impaired renal function
(serum urea 69 mg/dl, serum creatinine 1 5 mg/dl) and
low total protein value with hypoalbuminemia (6.4 and
3.2 g/dl, respectively). A chest X-ray was consistent with
bilateral interstitial edema and showed a stable lung-
tumor disease
The patient received an intravenous administration
of furosemide, high-dose dexamethasone and albumin,
with a rapid and complete clinical recovery.
No other chemotherapy was given and the patient
successfully underwent radical surgery.
Comments
This clinical report describes an enhancement of fluid
filtration followed by a systemic capillary leak syndrome
(SCLS) recurrently developed after gemcitabine (GCB)
administration, strongly suggesting a strict correlation
between symptoms and drug
The probable explanation of why SCLS did not occur
after GCB administration on day 1 of each cycle could
be the 4-day administration of 12 mg of dexamethasone
given daily as a nausea and vomiting prophylaxis. As a
matter of fact, when high-dose dexamethasone was
given with furosemide and albumin to treat SCLS, the
patient promptly recovered
Although there is no clear explanation why the patient
did not have a SCLS after the first cycle, the delayed
development of symptoms is consistent with reports on
GCB-induced pulmonary toxicity [6].
Even though many drugs are known to induce SCLS,
to our knowledge a correlation between SCLS and GCB
has never been reported. The detection of GCB-induced
SCLS is quite important, because this supports the
hypothesis that SCLS could be the possible pathogenic
way for the GCB-related acute respiratory distress syn-
drome (RDS) that is being recognized [6-8]. As ob-
served in patients given an intermediate dose and high
dose of ara-C, patients given GCB can also suffer a rare
but life-threatening RDS' authors reporting these cases
described some therapeutic effects from corticosteroids
and diuretics and postulated a capillary leak phenomenon
as the pathogenic mechanism of toxicity [6, 9].
Should patients develop SCLS during treatment with
GCB, we recommend the administration of high-dose
corticosteroid prophylaxis.
Any respiratory symptom should be promptly inves-
tigated in order to exclude lung toxicity that, if not
recognized, could lead to death.
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